NewLink Genetics Corporation (NASDAQ:NLNK) Files An 8-K Results of Operations and Financial Condition

NewLink Genetics Corporation (NASDAQ:NLNK) Files An 8-K Results of Operations and Financial Condition

Story continues below

Item 2.02. Results of Operations and Financial Condition.

On May 4, 2017, NewLink Genetics Corporation, a Delaware
corporation (the Company), issued a press release providing an
operational update and reporting financial results for the first
quarter ended March 31, 2017 (“Press Release”). A copy of the
Press Release and the First Quarter Financial Results
Presentation are attached hereto as Exhibits 99.1 and 99.2,
respectively, and are incorporated herein by reference.
The information in this Current Report, including Exhibits 99.1
and 99.2 attached hereto is furnished under Item 2.02 of this
report and shall not be deemed to be filed for purposes of
Section 18 of the Securities Exchange Act of 1934 (the Exchange
Act) or otherwise subject to the liabilities of that section, nor
shall be deemed incorporated by reference in any filing under the
Securities Act of 1933 or the Exchange Act, regardless of any
general incorporation language in such filing.
Section 9 – Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit Number
Description
99.1
Press Release, dated May 4, 2017, entitled NewLink
Genetics Corporation Reports First Quarter 2017
Financial Results and Updates Clinical Trial Guidance
99.2
First Quarter 2017 Financial Results Presentation


About NewLink Genetics Corporation (NASDAQ:NLNK)

NewLink Genetics Corporation is a biopharmaceutical company focused on discovering, developing and commercializing immunotherapeutic products for cancer treatment. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications. Its biologic product candidates are based on its HyperAcute immunotherapy technology platform, which is designed to stimulate the human immune system. Algenpantucel-L is its clinically advanced product candidate for patients with pancreatic cancer. Its additional HyperAcute cellular HyperAcute Cellular Immunotherapy product candidates in clinical development include tergenpumatucel-L and dorgenmeltucel-L for patients with advanced lung cancer and melanoma. It has two small-molecule product candidates in clinical development: GDC-0919 and indoximod. These product candidates are indoleamine-2, 3-dioxygenase (IDO) pathway inhibitors and focus on breaking the immune system’s tolerance to cancer.

NewLink Genetics Corporation (NASDAQ:NLNK) Recent Trading Information

NewLink Genetics Corporation (NASDAQ:NLNK) closed its last trading session down -0.33 at 17.72 with 563,749 shares trading hands.

An ad to help with our costs